Back to Search
WILLIAM MCGUIRE, MD
MD
Pulmonary Disease Physician
NPI: 1841684081IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
2025-01508(NC)
Critical Care Medicine (Internal Medicine) Physician
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
2025-01508(NC)
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
2025-01508(NC)
CMS Specialties
PrimaryPULMONARY DISEASE
Education
TULANE UNIVERSITY SCHOOL OF MEDICINE
Class of 2015
Research & Publications (20)
Beyond EBM: new directions for evidence-based public health.
PMID 16227667·Perspect Biol Med·2005
8-other
Current status of taxane and platinum-based chemotherapy in ovarian cancer.
PMID 12743128·J Clin Oncol·2003
6-review
High-dose chemotherapeutic approaches to ovarian cancer management.
PMID 10952126·Semin Oncol·2000
6-review
What has the Cochrane collaboration ever done for newborn infants?
PMID 19414431·Arch Dis Child Fetal Neonatal Ed·2010
8-other
Early trophic feeding for very low birth weight infants.
PMID 19588318·Cochrane Database Syst Rev·2009
1-meta
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
PMID 19075271·J Clin Oncol·2009
3-trial
Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.
PMID 19272639·Gynecol Oncol·2009
4-observational
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
PMID 19307994·J Immunother·2009
3-trial
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.
PMID 19195045·Cancer·2009
6-review
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
PMID 19224846·J Clin Oncol·2009
3-trial
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.
PMID 19156927·Cancer·2009
8-other
Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.
PMID 19524285·Gynecol Oncol·2009
3-trial
Tumour necrosis factor (--308A) polymorphism in very preterm infants with bronchopulmonary dysplasia: a meta-analysis.
PMID 19066187·Arch Dis Child Fetal Neonatal Ed·2009
1-meta
Enteral feeding regimens and necrotising enterocolitis in preterm infants: a multicentre case-control study.
PMID 17768154·Arch Dis Child Fetal Neonatal Ed·2009
4-observational
Prevention and treatment of invasive fungal infection in very low birthweight infants.
PMID 18838467·Arch Dis Child Fetal Neonatal Ed·2009
6-review
Cytokine gene polymorphisms in preterm infants with necrotising enterocolitis: genetic association study.
PMID 17768156·Arch Dis Child Fetal Neonatal Ed·2009
4-observational
Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
PMID 18588458·Expert Rev Anticancer Ther·2008
6-review
Tumour necrosis factor (-308A) polymorphism in pre-eclampsia: meta-analysis of 16 case-control studies.
PMID 19133041·Aust N Z J Obstet Gynaecol·2008
1-meta
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 130 MASON FARM RD FL 4
CHAPEL HILL, NC 27514 - Phone
- (919) 966-2531
Quick Facts
- NPI
- 1841684081
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile